CALL FOR ABSTRACTS
Abstract submission is now closed.
SUBMISISON DEADLINE: Monday, May 1, 2023
NOTIFICATION DATE: Friday, May 5, 2023
Encore posters are welcome!
We invite all registered meeting attendees to submit abstracts for posters of their latest research on the following topics:
- Acne and Rosacea
- Atopic Dermatitis
- Pediatric Dermatology
- Other Medical Dermatology Topics (Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, etc.)
All accepted abstracts will be displayed at the 18th Annual Women’s & Pediatric Dermatology Seminar, June 16-17, 2023 to be held at the The Hilton Inner Harbor Hotel in Baltimore, MD.
In addition, approved abstracts will also be submitted and indexed through our partner brand Read by QxMD. The platform drives awareness, dissemination and engagement with this content via the Read by QxMD platform, as an educational tactic to drive CQI. ‘Read’ works on iPhone, iPad, Android smartphones & tablets and any web-enabled device (including desktops), and uses channels such as mobile, email and push notification to connect with our global community of healthcare providers and researchers.
Download the App:
At least one (1) author must be registered for the in-person meeting to have their abstracts considered for oral presentation and/or poster display. All submissions accepted for oral presentation must also create a poster for display.
Fee: No fee for non-industry-sponsored abstracts; $495 per abstract for industry-sponsored abstracts.
Abstract Formatting and Content Guidelines
You must be registered for the meeting to have your abstract considered for a presentation.
- Language: English
- Authors: full last name, first name, affiliations, degrees and contact information
- Font: Arial
- Maximum of 3000 characters, including spaces (not including the title, authors, or affiliations)
- Maximum of 2 relevant tables or figures submitted as attachments (not embedded in the file): must be 600 dpi .jpg
- References must be included as parenthetical in-text citations - first author, et al, journal and year - (Cruz D, et al. Blood 2012)
- Full contact information of corresponding author (Please ensure that your email address is accurate, as all correspondence will be sent via email)
- Abstract text should preferably be in a "structured abstract" form with sections marked Background, Objectives, Methods, Results, Disclosures and Conclusions
- Abstracts containing non-generic drug names or personal patient information, or reporting studies with unidentified chemical compounds, drugs, or materials, will not be accepted.
If you have any questions, please contact Tristan Nelsen at firstname.lastname@example.org.